Merck’s Sotatercept Clears Phase III Trial Merck’s USD 11.5 billion acquisition of Acceleron last year was based on the promise of pulmonary arterial hypertension (PAH) candidate sotatercept, which has recently met the mark in a much-anticipated phase III trial. The STELLAR trial found that adding the activin re...
Find MoreMany players such as Immunogen, On Target Laboratories, ImmunoVaccine Technologies, OncoQuest, Precigen, and some others are involved in developing therapies to accelerate the Ovarian Cancer Market. Cancer, coronary heart disease, and stroke are the leading contributors of the mortality worldwide, estimated ...
Find MoreFDA grants priority review to Zejula Niraparib (Zejula) received a priority review by the U.S. FDA, in response to a supplemental New Drug Application (sNDA) submitted by Tesaro. The drug, acquired by GlaxoSmithKline along with the drugmaker Tesaro for USD 5.1 Million, has an action date of October 24, 2019. T...
Find MoreWorld Ovarian Cancer Day Every year on May 8TH women fighting Ovarian Cancer, their families, friends and supporters join hands to raise awareness about Ovarian Cancer. Ovarian cancer has the lowest survival rate of all female cancers. Ovarian Cancer can pose a real tough situation for every woman out there desp...
Find MoreOvarian Cancer is a type of cancer that starts in Ovaries when the cells in the ovaries keep on dividing abnormally. It can affect either one or both the ovaries. Cancers that start in the ovaries can metastasize to other parts of the body. Ovarian cancer is not a single disease but can be defined as a cluster of d...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.